These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1384 related items for PubMed ID: 9457395

  • 41. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM, Child JA, Cullen MH, Bailey NP, Woodruffe CM, Fletcher J, Earl H, Barnard D.
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [Abstract] [Full Text] [Related]

  • 42. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.
    Cancer; 2004 Nov 01; 101(9):2034-41. PubMed ID: 15455357
    [Abstract] [Full Text] [Related]

  • 43. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
    Rosenfeld CS, Przepiorka D, Schwinghammer TL, Buck DS, Bloom EJ, Shadduck RK.
    Exp Hematol; 1991 Jun 01; 19(5):317-21. PubMed ID: 2026183
    [Abstract] [Full Text] [Related]

  • 44. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE.
    Bone Marrow Transplant; 1997 Jan 01; 19(2):121-7. PubMed ID: 9116608
    [Abstract] [Full Text] [Related]

  • 45. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C.
    Bone Marrow Transplant; 1996 Dec 01; 18(6):1057-64. PubMed ID: 8971373
    [Abstract] [Full Text] [Related]

  • 46. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
    McQuaker I, Haynes A, Stainer C, Byrne J, Russell N.
    Bone Marrow Transplant; 1999 Oct 01; 24(7):715-22. PubMed ID: 10516673
    [Abstract] [Full Text] [Related]

  • 47. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
    Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J.
    Bone Marrow Transplant; 1990 May 01; 5(5):341-4. PubMed ID: 2190660
    [Abstract] [Full Text] [Related]

  • 48. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1996 Mar 01; 17(3):351-6. PubMed ID: 8704686
    [Abstract] [Full Text] [Related]

  • 49. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
    Biol Blood Marrow Transplant; 2005 Jan 01; 11(1):13-22. PubMed ID: 15625540
    [Abstract] [Full Text] [Related]

  • 50. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
    Bone Marrow Transplant; 2004 Nov 01; 34(9):781-6. PubMed ID: 15354206
    [Abstract] [Full Text] [Related]

  • 51. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.
    Miniero R, Brach del Prever A, Vassallo E, Nesi F, Busca A, Fagioli F, Albiani R, Picci P, Bacci G, Madon E.
    Bone Marrow Transplant; 1998 Dec 01; 22 Suppl 5():S37-40. PubMed ID: 9989888
    [Abstract] [Full Text] [Related]

  • 52. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF, Suryadevara U, Pereyra V, Colón D, Fontelonga A, Mackintosh FR, Hall SW, Ascensão JL.
    Exp Hematol; 2006 Nov 01; 34(11):1443-50. PubMed ID: 17046563
    [Abstract] [Full Text] [Related]

  • 53. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
    Magagnoli M, Castagna L, Balzarotti M, Sarina B, Timofeeva I, Bertuzzi A, Compasso S, Nozza A, Siracusano L, Santoro A.
    Am J Hematol; 2003 Aug 01; 73(4):267-72. PubMed ID: 12879431
    [Abstract] [Full Text] [Related]

  • 54. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Fermé C, Gisselbrecht C.
    Bone Marrow Transplant; 1999 Oct 01; 24(7):747-55. PubMed ID: 10516678
    [Abstract] [Full Text] [Related]

  • 55. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
    Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, Radford JA.
    Bone Marrow Transplant; 1999 Aug 01; 24(3):271-7. PubMed ID: 10455365
    [Abstract] [Full Text] [Related]

  • 56. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J.
    Bone Marrow Transplant; 1995 Nov 01; 16(5):655-61. PubMed ID: 8547862
    [Abstract] [Full Text] [Related]

  • 57. [High-dose chemotherapy supported by peripheral blood stem cells to treat intermediate--and high-grade non-Hodgkin's lymphomas].
    Ji Y, Ji S, Ju X.
    Zhonghua Zhong Liu Za Zhi; 1996 Nov 01; 18(6):471-5. PubMed ID: 9387307
    [Abstract] [Full Text] [Related]

  • 58. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.
    Bone Marrow Transplant; 2000 Apr 01; 25(7):697-703. PubMed ID: 10745253
    [Abstract] [Full Text] [Related]

  • 59. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G.
    Eur J Haematol Suppl; 2001 Jul 01; 64():14-20. PubMed ID: 11486395
    [Abstract] [Full Text] [Related]

  • 60. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podestà M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A.
    Haematologica; 1998 Oct 01; 83(10):904-9. PubMed ID: 9830799
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 70.